journal article·2025-12-31

Self-Regulated Cobalt–Zinc–Ferrite Nanoprobe for Targeted Chemomagnetic Hyperthermia in Cancer Therapy

Mounika Choppadandi, Khyati Parmar, Sumanta Ghosh, Srinivasa Rao K, K. H. Rao, Aditya A. Singh, Pankaj Sharma, Hemant Kumar, Hema L. Turubilli, Subhash C. Chauhan, Murali M. Yallapu, Govinda Kapusetti

ACS Applied Materials & Interfaces· Volume 17· Issue 52
Publisher page

Abstract

High Resolution Image Download MS PowerPoint Slide Chemo-magnetic hyperthermia is a promising alternative anticancer treatment strategy employed to synergize the therapeutic efficacy of chemotherapy and magnetic hyperthermia. Despite its potential efficacy, most chemo-magnetic hyperthermia strategies are limited owing to limited in vivo thermal conversion ability and inadequate local therapeutic temperatures with nontargeted, uncontrolled release of anticancer agents. Herein, we developed a targeted formulation of anticancer drug-loaded nanoprobe for site-specific chemo-magnetic hyperthermia. The engineered nanoprobe comprising doxorubicin-loaded cobalt–zinc–ferrite nanoparticles, surface-modified with estrone-3-hemisuccinate (TMNPs), exhibits enhanced magnetic properties, including elevated saturation magnetization and the ability to a prolonged constant therapeutic temperature (42–46 °C) under an alternating magnetic field of 20 mT. Targeted delivery was achieved via specific interaction with estrogen receptors (ERs), which resulted in markedly higher apoptosis (∼97%) in ER-positive MCF-7 cells compared to ER-negative controls. In vivo evaluation using a xenograft murine model of breast cancer demonstrated the efficacy of TMNPs in orchestrating a multifaceted therapeutic response through the synergistic integration of chemotherapeutic and hyperthermic modalities. Immunofluorescence analysis of tumor tissues post-treatment revealed the localized induction of thermal stress and upregulation of Heat Shock Protein 70 (HSP-70), a biomarker linked to enhanced immune cell infiltration and activation within the tumor microenvironment. Overall, this study presents a methodical effort to explore the effectiveness of cobalt–zinc–ferrite nanoprobe for chemo-magnetic hyperthermia effects that can be used for efficient, patient-specific, targeted, controlled anticancer therapy through chemodynamic–magnetic–thermal synergistic therapy.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoparticle-Based Drug Delivery · Nanoplatforms for cancer theranostics · Intraperitoneal and Appendiceal Malignancies

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

National Institute of Pharmaceutical Education and Research Ahmedabad

Laboratory for Biointerfaces

Swiss Federal Laboratories for Materials Science and Technology-EMPA, ETH

Department of Physics

Andhra University

Dr. V. S. Krishna Government Degree College

Division of Cancer Immunology, Department of Medicine and Oncology, School of Medicine

University of Texas Rio Grande Valley

South Texas Center of Excellence for Cancer Research, School of Medicine

National Institute of Pharmaceutical Education and Research Kolkata

Funding

National Institute of Pharmaceutical Education and Research, Ahmedabad · Cancer Prevention and Research Institute of Texas · National Institutes of Health

References (51)

Show source-provided references
1. Organization, W. H. Global Breast Cancer Initiative , 2022.
2. 10.1016/S1470-2045(21)00071-110.1016/S1470-2045(21)00071-1 ↗
3. 10.1038/nrclinonc.2015.7310.1038/nrclinonc.2015.73 ↗
4. 10.1038/s41571-021-00565-210.1038/s41571-021-00565-2 ↗
5. 10.1038/s41416-024-02589-810.1038/s41416-024-02589-8 ↗
6. 10.1038/s41571-023-00832-410.1038/s41571-023-00832-4 ↗
7. 10.1038/s41587-023-02060-810.1038/s41587-023-02060-8 ↗
8. 10.1021/acsami.3c1888810.1021/acsami.3c18888 ↗
9. 10.1186/s13287-022-02885-110.1186/s13287-022-02885-1 ↗
10. 10.1039/D3NR05082C10.1039/D3NR05082C ↗
11. 10.1002/advs.20230617810.1002/advs.202306178 ↗
12. 10.1016/j.colsurfb.2024.11375410.1016/j.colsurfb.2024.113754 ↗
13. 10.1016/j.jallcom.2019.04.24210.1016/j.jallcom.2019.04.242 ↗
14. 10.1016/j.matpr.2021.04.28910.1016/j.matpr.2021.04.289 ↗
15. 10.1016/j.jddst.2024.10558110.1016/j.jddst.2024.105581 ↗
16. 10.1021/acsomega.3c0725110.1021/acsomega.3c07251 ↗
17. 10.1016/j.jmmm.2004.09.13810.1016/j.jmmm.2004.09.138 ↗
18. 10.1021/acsabm.1c0045210.1021/acsabm.1c00452 ↗
19. 10.1016/j.pbiomolbio.2017.10.00110.1016/j.pbiomolbio.2017.10.001 ↗
20. 10.1002/advs.20241042710.1002/advs.202410427 ↗
21. 10.1016/j.colsurfb.2022.11307710.1016/j.colsurfb.2022.113077 ↗
22. 10.1002/adma.20230828610.1002/adma.202308286 ↗
23. 10.1021/acsbiomaterials.9b0122410.1021/acsbiomaterials.9b01224 ↗
24. 10.1186/s12885-024-12129-510.1186/s12885-024-12129-5 ↗
25. 10.1016/j.jcis.2025.01.14910.1016/j.jcis.2025.01.149 ↗
26. BERKEL, C. Estrogen receptor (ER)-and progesterone receptor (PR)-dependent expression of NINJ1, a cell-surface executioner of active cell rupture, in breast cancer, with implications in prognosis. 2024.10.21203/rs.3.rs-3981303/v1 ↗
27. 10.1016/j.mtchem.2022.10115810.1016/j.mtchem.2022.101158 ↗
28. 10.1016/j.ijbiomac.2020.08.17210.1016/j.ijbiomac.2020.08.172 ↗
29. 10.1021/acssuschemeng.7b0213010.1021/acssuschemeng.7b02130 ↗
30. 10.7150/thno.4080510.7150/thno.40805 ↗
31. 10.1021/acsomega.3c0783510.1021/acsomega.3c07835 ↗
32. 10.1016/j.colsurfb.2021.11193110.1016/j.colsurfb.2021.111931 ↗
33. 10.1007/s12668-023-01202-110.1007/s12668-023-01202-1 ↗
34. 10.1103/PhysRevLett.102.01720110.1103/PhysRevLett.102.017201 ↗
35. 10.1016/j.jmmm.2022.16914010.1016/j.jmmm.2022.169140 ↗
36. 10.1016/j.cclet.2025.11181710.1016/j.cclet.2025.111817 ↗
37. 10.1142/S179398441550002610.1142/S1793984415500026 ↗
38. 10.1002/adtp.20200026710.1002/adtp.202000267 ↗
39. 10.1021/acsomega.2c0596210.1021/acsomega.2c05962 ↗
40. 10.1021/acs.jpcc.9b0679010.1021/acs.jpcc.9b06790 ↗
41. 10.1016/j.matchemphys.2021.12454610.1016/j.matchemphys.2021.124546 ↗
42. 10.1054/bjoc.2000.153810.1054/bjoc.2000.1538 ↗
43. 10.1097/01.MP.0000062657.30170.9210.1097/01.MP.0000062657.30170.92 ↗
44. 10.1289/ehp.100220110.1289/ehp.1002201 ↗
45. 10.1039/D1NJ01415C10.1039/D1NJ01415C ↗
46. 10.1002/smll.20200524110.1002/smll.202005241 ↗
47. 10.1177/1534735424124209410.1177/15347354241242094 ↗
48. 10.1016/j.bcp.2023.11550510.1016/j.bcp.2023.115505 ↗
49. 10.1126/sciadv.adg959310.1126/sciadv.adg9593 ↗
50. 10.7150/jca.8866810.7150/jca.88668 ↗
51. 10.1021/acsnano.0c0091010.1021/acsnano.0c00910 ↗